Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atorvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 3/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.98 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.98 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.98 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.98 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.84 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.84 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.84 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.84 |
| ▸ | RHOC | P08134 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.84 |
| ▸ | THRB | P10828 | 1/20 | 0.84 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.84 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.84 |
| ▸ | PDE6D | O43924 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atorvastatin SCHEMBL41065 | 1.00 | ABCB11 (0.98) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL249095 | 0.99 | ABCB11 (0.97) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL909379 | 0.99 | ABCB11 (0.97) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL137843 | 0.99 | ABCB11 (0.97) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL3832 | 0.99 | ABCB11 (1.00) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL6064039 | 0.99 | ABCB11 (1.00) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL7703363 | 0.99 | ABCB11 (1.00) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL7037659 | 0.99 | ABCB11 (1.00) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL5072672 | 0.99 | ABCB11 (1.00) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL137842 | 0.98 | ABCB11 (0.98) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11975108-B2 | Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation | CATALENT ONTARIO LIMITED (CA) | 2024-05-07 | — | — | US | disclosed |
| US-20230233472-A1 | METHODS OF PREPARING MULTIPHASE STATIN AND OMEGA-3 FATTY ACID SOFT CAPSULE FORMULATIONS | CATALENT ONTARIO LIMITED (CA) | 2023-07-27 | — | — | US | disclosed |
| EP-2575787-B1 | PHARMACEUTICAL FORMULATIONS OF STATINS AND OMEGA-3 FATTY ACIDS FOR ENCAPSULATION | CATALENT ONTARIO LTD (CA) | 2020-05-27 | — | — | EP | disclosed |
| US-20130115281-A1 | PHARMACEUTICAL FORMULATIONS OF STATINS AND OMEGA-3 FATTY ACIDS FOR ENCAPSULATION | ACCUCAPS INDUSTRIES LIMITED (CA) | 2013-05-09 | — | — | US | disclosed |
| EP-2575787-A1 | PHARMACEUTICAL FORMULATIONS OF STATINS AND OMEGA-3 FATTY ACIDS FOR ENCAPSULATION | Accucaps Industries Limited (CA) | 2013-04-10 | — | — | EP | disclosed |
| EP-2432458-A2 | INGESTIBLE EVENT MARKERS COMPRISING AN INGESTIBLE COMPONENT | Proteus Biomedical, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2427178-A2 | DERMAL DELIVERY COMPOSITIONS COMPRISING ACTIVE AGENT-CALCIUM PHOSPHATE PARTICLE COMPLEXES AND METHODS OF USING THE SAME | Laboratory Skin Care, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120059257-A1 | Ingestible Event Markers Comprising an Ingestible Component | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20110212090-A1 | Combinatorial Analysis and Repair | DAKO DENMARK A/S | 2011-09-01 | — | — | US | disclosed |
| US-20110189239-A1 | Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same | LABORATORY SKIN CARE, INC. | 2011-08-04 | — | — | US | disclosed |
| US-20110105864-A1 | Pharma-Informatics System | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110098356-A1 | Production and Purification of Esters of Polyunsaturated Fatty Acids | MARTEK BIOSCIENCES CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-7842716-B2 | Treating vascular events with statins by inhibiting PAR-1 and PAR-4 | HeartDrug Research, LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-20060034831-A1 | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors | WYETH | 2006-02-16 | — | — | US | disclosed |
| US-20020198202-A1 | Combination of a PTPase inhibitor and an antilipemic agent | WYETH (US) | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060034831-A1 | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors | DPP8, IGFBP1, IGFBP5 | HMGCR 634/4885ABCB11 2680/4885SLCO1B1 2728/4885 |
| US-20020198202-A1 | Combination of a PTPase inhibitor and an antilipemic agent | PTPN6, PTPN1, PNLIP | HMGCR 53/4885ABCB11 440/4885SLCO1B1 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.